Thyrocare has announced that it has entered into an agreement to acquire the pathology diagnostic business of Punjab-based Polo Labs. This acquisition by the PharmEasy-owned platform aims to expand Thyrocare’s reach in the northern parts of India and further solidify its position as a dominant player in the diagnostic industry.
This strategic move to acquire Polo Labs is poised to enhance Thyrocare’s market position and revolutionize diagnostic services. The acquisition includes integrating 14 Polo Labs’ laboratories located in Punjab, Haryana, and Himachal Pradesh into Thyrocare’s network, further extending its diagnostic capabilities and service offerings.
Strategic Expansion
Thyrocare’s acquisition of Polo Labs’ pathology diagnostic business is a calculated step toward strategic expansion.
By integrating Polo Labs’ established diagnostic services, Thyrocare aims to:
- Broaden its portfolio and geographical reach.
- Strengthen its foothold in the diagnostics market.
- Serve a larger customer base with a more comprehensive range of tests and services.
By combining Polo Labs’ network with Thyrocare’s infrastructure, the company expects to:
- Deliver faster turnaround times
- Increase convenience for patients
- Offer a wider range of diagnostic services
Thyrocare CEO Rahul Guha Speaks About Acquisition
Rahul Guha, Managing Director and CEO of Thyrocare Technologies, commented, “his strategic acquisition will enhance our diagnostic capabilities and service offerings, leveraging Polo Labs’ existing widespread network in North India. We are committed to a seamless integration and look forward to the growth and innovation this acquisition will bring. Together, we will continue to provide exceptional diagnostic services to a broader client base.”
Thyrocare further stated in its press release, “As the company continues to grow its reach and capabilities, it remains committed to providing high-quality diagnostic services to communities across India.”
About Thyrocare
In 2021, PharmEasy acquired Thyrocare, a publicly-listed diagnostics chain, further enhancing its capabilities and market reach.
Thyrocare is committed to providing high-quality diagnostic services at affordable prices to laboratories and hospitals both in India and internationally. The company maintains a presence in over 2,000 cities globally. Thyrocare operates a fully automated diagnostic laboratory in Navi Mumbai, processing over 60,000 specimens and conducting over 300,000 diagnostic and screening investigations daily.
Recently, Thyrocare reported a significant 35% increase in profit after tax, reaching INR 23.5 Cr in Q1 FY25, up from INR 17.4 Cr in the same quarter of the previous fiscal year.
About Polo Labs
Polo Labs has established a reputable presence in pathology diagnostics within Northern India. As a key player in this space, Polo Labs operates 14 laboratories across Punjab, Haryana, Himachal Pradesh, and Jammu & Kashmir.
The lab is renowned for its commitment to providing affordable and accessible diagnostic services, utilizing modern and efficient technology to meet the high-quality expectations of its clientele.
Final Word
The acquisition reflects Thyrocare’s commitment to improving healthcare infrastructure and service accessibility in the region. Thyrocare’s continuous focus on automation and quality, coupled with Polo Labs’ established presence in the northern region, is poised to create a formidable partnership in the diagnostic services market.
Want to buy unlisted shares like Pharmeasy, NSE, and Chennai Super Kings? At Stockify we help our investors in finding alternative investment opportunities by investing in trending unlisted shares and increasing their portfolio wealth. Connect with our experts to know more.
